View : 70 Download: 0
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study
- Title
- The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study
- Authors
- Choi; Myeong Geun; Kim; Yeon Joo; Lee; Jae Cheol; Ji; Wonjun; Oh; In-Jae; Sung Yong; Yoon; Seong Hoon; Shin Yup; Jeong Eun; Eun Young; Chang-Min
- Ewha Authors
- 최명근
- SCOPUS Author ID
- 최명근
- Issue Date
- 2024
- Journal Title
- Cancer Research and Treatment
- ISSN
- 1598-2998
- Citation
- Cancer Research and Treatment vol. 56, no. 2, pp. 422 - 429
- Keywords
- Atezolizumab; Real-world; Small cell lung carcinoma
- Publisher
- Korean Cancer Association
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings. Materials and Methods In this multicenter prospective cohort study, patients with ES-SCLC receiving or scheduled to receive atezolizumab in combination with etoposide and carboplatin were enrolled between June 2021 and August 2022. The primary outcomes were progression-free survival (PFS) and the 1-year overall survival (OS) rate. Results A total of 100 patients with ES-SCLC were enrolled from seven centers. Median age was 69 years, and 6% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2. The median PFS was 6.0 months, the 1-year OS rate was 62.2%, and the median OS was 13.5 months. An ECOG PS of 2-3 and progressive disease as the best response were poor prognostic factors for PFS, while an ECOG PS of 2-3 and brain metastasis were associated with poor prognosis for OS. In addition, consolidative thoracic radiotherapy was found to be an independent favorable prognostic factor for OS (hazard ratio, 0.336; p=0.021). Grade ≥ 3 treatment-related adverse events were observed in 7% of patients, with treatment-related deaths occurring in 2% of patients. Conclusion We provided evidence of the favorable real-world effectiveness and safety of atezolizumab plus chemotherapy in ES-SCLC patients, including in the elderly and those with poor ECOG PS. Additional consolidative thoracic radiotherapy may also benefit ES-SCLC patients. © 2024 Korean Cancer Association. All rights reserved.
- DOI
- 10.4143/crt.2023.913
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML